277 related articles for article (PubMed ID: 27166684)
1. The Impact of Conventional and Biological Disease Modifying Antirheumatic Drugs on Bone Biology. Rheumatoid Arthritis as a Case Study.
Barreira SC; Fonseca JE
Clin Rev Allergy Immunol; 2016 Aug; 51(1):100-9. PubMed ID: 27166684
[TBL] [Abstract][Full Text] [Related]
2. The effects of TNF α antagonist therapy on bone metabolism in rheumatoid arthritis: a systematic review.
Sakthiswary R; Das S
Curr Drug Targets; 2013 Dec; 14(13):1552-7. PubMed ID: 23848441
[TBL] [Abstract][Full Text] [Related]
3. Disease-modifying antirheumatic drugs and bone mass in rheumatoid arthritis.
Di Munno O; Delle Sedie A; Rossini M; Adami S
Clin Exp Rheumatol; 2005; 23(2):137-44. PubMed ID: 15895881
[TBL] [Abstract][Full Text] [Related]
4. Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis.
Suematsu A; Tajiri Y; Nakashima T; Taka J; Ochi S; Oda H; Nakamura K; Tanaka S; Takayanagi H
Mod Rheumatol; 2007; 17(1):17-23. PubMed ID: 17278017
[TBL] [Abstract][Full Text] [Related]
5. [Rheumatoid arthritis and bone -periarticular and systemic bone loss-].
Ono K; Ohashi S; Tanaka S
Clin Calcium; 2013 Feb; 23(2):249-55. PubMed ID: 23354093
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
[TBL] [Abstract][Full Text] [Related]
7. New biologics for rheumatoid arthritis.
Choy E
J R Coll Physicians Edinb; 2011 Sep; 41(3):234-7. PubMed ID: 21949922
[TBL] [Abstract][Full Text] [Related]
8. [Secondary osteoporosis. Bisphosphonates as a possible strategy for the prevention of bone destruction in rheumatoid arthritis].
Suzuki Y
Clin Calcium; 2007 Dec; 17(12):1909-13. PubMed ID: 18057668
[TBL] [Abstract][Full Text] [Related]
9. Relation among anti-rheumatic drug therapy, CD14(+)CD16(+) blood monocytes and disease activity markers (DAS28 and US7 scores) in rheumatoid arthritis: A pilot study.
Amoruso A; Sola D; Rossi L; Obeng JA; Fresu LG; Sainaghi PP; Pirisi M; Brunelleschi S
Pharmacol Res; 2016 May; 107():308-314. PubMed ID: 27045818
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system.
Tanaka Y; Ohira T
Curr Opin Pharmacol; 2018 Jun; 40():110-119. PubMed ID: 29702364
[TBL] [Abstract][Full Text] [Related]
11. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
Ranganath VK; Furst DE
Clin Geriatr Med; 2005 Aug; 21(3):649-69, viii. PubMed ID: 15911212
[TBL] [Abstract][Full Text] [Related]
12. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
13. The effect of disease-modifying antirheumatic drugs (DMARDs) on bone homeostasis in rheumatoid arthritis (RA) patients.
Khoshroo A; Ramezani K; Moghimi N; Bonakdar M; Ramezani N
Inflammopharmacology; 2023 Apr; 31(2):689-697. PubMed ID: 36348208
[TBL] [Abstract][Full Text] [Related]
14. Are glucocorticoids harmful to bone in early rheumatoid arthritis?
Lems WF
Ann N Y Acad Sci; 2014 May; 1318():50-4. PubMed ID: 24739059
[TBL] [Abstract][Full Text] [Related]
15. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).
Karsdal MA; Schett G; Emery P; Harari O; Byrjalsen I; Kenwright A; Bay-Jensen AC; Platt A
Semin Arthritis Rheum; 2012 Oct; 42(2):131-9. PubMed ID: 22397953
[TBL] [Abstract][Full Text] [Related]
16. [Biochemical markers of bone turnover. New aspect. Therapy of rheumatoid arthritis for bone metabolic marker].
Okada Y; Nawata M; Tanaka Y
Clin Calcium; 2009 Aug; 19(8):1186-90. PubMed ID: 19638703
[TBL] [Abstract][Full Text] [Related]
17. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis.
Turiel M; Tomasoni L; Sitia S; Cicala S; Gianturco L; Ricci C; Atzeni F; De Gennaro Colonna V; Longhi M; Sarzi-Puttini P
Cardiovasc Ther; 2010 Oct; 28(5):e53-64. PubMed ID: 20337633
[TBL] [Abstract][Full Text] [Related]
18. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
Ranganath VK; Furst DE
Rheum Dis Clin North Am; 2007 Feb; 33(1):197-217. PubMed ID: 17367700
[TBL] [Abstract][Full Text] [Related]
19. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.
Cohen SB; Dore RK; Lane NE; Ory PA; Peterfy CG; Sharp JT; van der Heijde D; Zhou L; Tsuji W; Newmark R;
Arthritis Rheum; 2008 May; 58(5):1299-309. PubMed ID: 18438830
[TBL] [Abstract][Full Text] [Related]
20. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis.
Feely MG; O'Dell JR
Curr Opin Rheumatol; 2010 May; 22(3):316-20. PubMed ID: 20190639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
